Physician profile
Ann E Rehan
NPI 1891792206
$272.37
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.90 · 2020: $15.12 · 2021: $86.30 · 2022: $158.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $60.54 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $36.72 | 2021 | |
| Corium, LLC | $34.10 | 2022 | |
| Abbvie INC. | $21.85 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.60 | 2022 | |
| Tris Pharma INC | $21.39 | 2022 | |
| Genzyme Corporation | $17.05 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.31 | 2021 | |
| Neos Therapeutics, Lp | $15.12 | 2020 | |
| Sobi, INC | $14.79 | 2022 | |
| Ironshore Pharmaceuticals INC. | $12.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Rehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.